Literature DB >> 32690569

Use of phenytoin for treatment of tacrolimus toxicity with superimposed sepsis.

Aditi Sharma1, Krista A Wahby2, Mohammed Inany3, Sarah J Lee3.   

Abstract

A 40-year-old woman with a history of chronic graft-versus-host-disease on immunosuppression with tacrolimus presented to the hospital with somnolence, confusion and muscle cramps over a few days. She was found to have hypertension, hyperglycaemia and acute kidney injury with an elevated blood tacrolimus level of greater than 120 ng/mL (reference range 5-15 ng/mL). Discontinuation of tacrolimus with concomitant administration of intravenous phenytoin led to the successful reduction of elevated tacrolimus concentrations and the resolution of her symptoms. Tacrolimus is metabolised by the cytochrome P (CYP) 450 3A enzyme system, and utilisation of CYP 3A inducers to accelerate its clearance may be used as a successful therapy to treat tacrolimus toxicity. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  acute renal failure; adult intensive care; malignant disease and immunosuppression; toxicology

Mesh:

Substances:

Year:  2020        PMID: 32690569      PMCID: PMC7373311          DOI: 10.1136/bcr-2020-234839

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment.

Authors:  Marvin M Goldenberg
Journal:  P T       Date:  2010-07

Review 2.  Therapeutic monitoring of calcineurin inhibitors for the nephrologist.

Authors:  Jeffrey Schiff; Edward Cole; Marcelo Cantarovich
Journal:  Clin J Am Soc Nephrol       Date:  2007-02-14       Impact factor: 8.237

3.  Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy.

Authors:  Hiba Arif; Richard Buchsbaum; Joanna Pierro; Michael Whalen; Jessica Sims; Stanley R Resor; Carl W Bazil; Lawrence J Hirsch
Journal:  Arch Neurol       Date:  2010-04

Review 4.  Phenytoin poisoning.

Authors:  Simon Craig
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 5.  Mode of action of tacrolimus (FK506): molecular and cellular mechanisms.

Authors:  A W Thomson; C A Bonham; A Zeevi
Journal:  Ther Drug Monit       Date:  1995-12       Impact factor: 3.681

Review 6.  Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation.

Authors:  M A Sikma; E M van Maarseveen; E A van de Graaf; J H Kirkels; M C Verhaar; D W Donker; J Kesecioglu; J Meulenbelt
Journal:  Am J Transplant       Date:  2015-06-04       Impact factor: 8.086

7.  Acute tacrolimus toxicity in a non-transplant patient.

Authors:  Ayrn D O'Connor; Daniel E Rusyniak; James Mowry
Journal:  Clin Toxicol (Phila)       Date:  2008-11       Impact factor: 4.467

Review 8.  Cardiovascular adverse effects of phenytoin.

Authors:  B Guldiken; J Rémi; Soheyl Noachtar
Journal:  J Neurol       Date:  2015-12-08       Impact factor: 4.849

9.  FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation.

Authors:  J W Fay; J R Wingard; J H Antin; R H Collins; L A Piñeiro; B R Blazar; R Saral; B E Bierer; D Przepiorka; W E Fitzsimmons; R M Maher; D J Weisdorf
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

Review 10.  Pharmacotherapy for Status Epilepticus.

Authors:  Eugen Trinka; Julia Höfler; Markus Leitinger; Francesco Brigo
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.